On 2016 Jan 08, Andrea Messori commented:

Drug-drug interactions in oncology

A.Messori, HTA Unit, Regional Health Service, 50100 Firenze, Italy and SIFACT (Società Italiana di Farmacia Clinica e Terapia), 20100 Milano

In the field of oncology, drug-drug interactions (DDIs) represent a topic in which a large amount of information is available. Hence, a critical selection in this area is generally thought to be needed to maximize the usefulness of recommendations and to avoid an overload of messages. In this selection process, two criteria are most frequently advocated: (1): prioritizing the DDIs showing a marked clinical relevance (that, in the main data banks, are denoted as major interactions or contra-indications); (2): prioritizing those DDIs the frequency of which is not negligible and has been documented in the real-world setting. The first point is adequately addressed by the scores assigned to single DDIs in the most authoritative data banks (e.g. Micromedex). As regards the second point, the reference list reported below indicates which DDIs have been most frequently found in the main studies conducted on this topic in cancer patients. References 1. Carcelero E, Anglada H, Tuset M, Creus N. Interactions between oral antineoplastic agents and concomitant medication: a systematic review. Expert Opin Drug Saf. 2013 May;12(3):403-20. doi: 10.1517/14740338.2013.784268. Epub 2013 Apr 16. Review. PubMed PMID: 23586848.

1. Chan A, Tan SH, Wong CM, Yap KY, Ko Y. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi-survey of oncology pharmacists. Clin Ther. 2009;31 Pt 2:2379-86. doi: 10.1016/j.clinthera.2009.11.008. PubMed PMID: 20110047.

2. Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud JM, Galpérine T, Abouelfath A, Valentino R, Dupon M, Hébert G, Moore N. Drug-drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1227-33. PubMed PMID: 17879355.

3. Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, Mignot L. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol.2011 Jun;78(3):220-6. doi: 10.1016/j.critrevonc.2010.05.004. Epub 2010 Jul 1. Review. PubMed PMID: 20594867.

4. Kotlinska-Lemieszek A, Klepstad P, Haugen DF. Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review. Drug Des Devel Ther. 2015 Sep 16;9:5255-67. doi: 10.2147/DDDT.S86983. eCollection 2015. Review. PubMed PMID: 26396499; PubMed Central PMCID: PMC4577251.

5. Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. J Clin Pharm Ther. 2014 Jun;39(3):259-65. doi: 10.1111/jcpt.12134. Epub 2014 Jan 13. PubMed PMID:24417304.

6. Miranda V, Fede A, Nobuo M, Ayres V, Giglio A, Miranda M, Riechelmann RP. Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage. 2011 Sep;42(3):342-53. doi: 10.1016/j.jpainsymman.2010.11.014. Epub 2011 Mar 31. PubMed PMID: 21454043.

7. Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009 Dec;20(12):1907-12. doi: 10.1093/annonc/mdp369. Epub 2009 Aug 27. Review. PubMed PMID: 19713244.

8. Stoll P, Kopittke L. Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study. Int J Clin Pharm. 2015 Jun;37(3):475-84. doi: 10.1007/s11096-015-0083-6. Epub 2015 Feb 25. PubMed PMID: 25711852.

9. Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol. 2015 Feb;79(2):241-53. doi:10.1111/bcp.12496. Review. PubMed PMID: 25125025; PubMed Central PMCID: PMC4309630.

10. Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, Bell JS. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer. 2014 Jul;22(7):1727-34. doi: 10.1007/s00520-014-2171-x. Epub 2014 Mar 2. Erratum in: Support Care Cancer. 2014 Jul;22(7):1735. PubMed PMID:24584682.

11. van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013 Mar 19;108(5):1071-8. doi: 10.1038/bjc.2013.48. Epub 2013 Feb 14. PubMed PMID: 23412102; PubMed CentralPMCID: PMC3619066.

12. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-druG interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014 Jul;15(8):e315-26. doi: 10.1016/S1470-2045(13)70579-5. Review. PubMed PMID: 24988935.

13. Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010 Oct;32(5):575-80. doi: 10.1007/s11096-010-9410-0. Epub 2010 Jul 20.PubMed PMID: 20645002.

On 2016 Jan 08, Andrea Messori commented:

Drug-drug interactions in oncology

A.Messori, HTA Unit, Regional Health Service, 50100 Firenze, Italy and SIFACT (Società Italiana di Farmacia Clinica e Terapia), 20100 Milano

In the field of oncology, drug-drug interactions (DDIs) represent a topic in which a large amount of information is available. Hence, a critical selection in this area is generally thought to be needed to maximize the usefulness of recommendations and to avoid an overload of messages. In this selection process, two criteria are most frequently advocated: (1): prioritizing the DDIs showing a marked clinical relevance (that, in the main data banks, are denoted as major interactions or contra-indications); (2): prioritizing those DDIs the frequency of which is not negligible and has been documented in the real-world setting. The first point is adequately addressed by the scores assigned to single DDIs in the most authoritative data banks (e.g. Micromedex). As regards the second point, the reference list reported below indicates which DDIs have been most frequently found in the main studies conducted on this topic in cancer patients. References 1. Carcelero E, Anglada H, Tuset M, Creus N. Interactions between oral antineoplastic agents and concomitant medication: a systematic review. Expert Opin Drug Saf. 2013 May;12(3):403-20. doi: 10.1517/14740338.2013.784268. Epub 2013 Apr 16. Review. PubMed PMID: 23586848.

1. Chan A, Tan SH, Wong CM, Yap KY, Ko Y. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi-survey of oncology pharmacists. Clin Ther. 2009;31 Pt 2:2379-86. doi: 10.1016/j.clinthera.2009.11.008. PubMed PMID: 20110047.

2. Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud JM, Galpérine T, Abouelfath A, Valentino R, Dupon M, Hébert G, Moore N. Drug-drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1227-33. PubMed PMID: 17879355.

3. Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, Mignot L. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol.2011 Jun;78(3):220-6. doi: 10.1016/j.critrevonc.2010.05.004. Epub 2010 Jul 1. Review. PubMed PMID: 20594867.

4. Kotlinska-Lemieszek A, Klepstad P, Haugen DF. Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review. Drug Des Devel Ther. 2015 Sep 16;9:5255-67. doi: 10.2147/DDDT.S86983. eCollection 2015. Review. PubMed PMID: 26396499; PubMed Central PMCID: PMC4577251.

5. Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. J Clin Pharm Ther. 2014 Jun;39(3):259-65. doi: 10.1111/jcpt.12134. Epub 2014 Jan 13. PubMed PMID:24417304.

6. Miranda V, Fede A, Nobuo M, Ayres V, Giglio A, Miranda M, Riechelmann RP. Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage. 2011 Sep;42(3):342-53. doi: 10.1016/j.jpainsymman.2010.11.014. Epub 2011 Mar 31. PubMed PMID: 21454043.

7. Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009 Dec;20(12):1907-12. doi: 10.1093/annonc/mdp369. Epub 2009 Aug 27. Review. PubMed PMID: 19713244.

8. Stoll P, Kopittke L. Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study. Int J Clin Pharm. 2015 Jun;37(3):475-84. doi: 10.1007/s11096-015-0083-6. Epub 2015 Feb 25. PubMed PMID: 25711852.

9. Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol. 2015 Feb;79(2):241-53. doi:10.1111/bcp.12496. Review. PubMed PMID: 25125025; PubMed Central PMCID: PMC4309630.

10. Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, Bell JS. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer. 2014 Jul;22(7):1727-34. doi: 10.1007/s00520-014-2171-x. Epub 2014 Mar 2. Erratum in: Support Care Cancer. 2014 Jul;22(7):1735. PubMed PMID:24584682.

11. van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013 Mar 19;108(5):1071-8. doi: 10.1038/bjc.2013.48. Epub 2013 Feb 14. PubMed PMID: 23412102; PubMed CentralPMCID: PMC3619066.

12. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-druG interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014 Jul;15(8):e315-26. doi: 10.1016/S1470-2045(13)70579-5. Review. PubMed PMID: 24988935.

13. Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010 Oct;32(5):575-80. doi: 10.1007/s11096-010-9410-0. Epub 2010 Jul 20.PubMed PMID: 20645002.